Genomic Medicine Sweden, GMS, has entered into an agreement with the Swedish life science sector’s trade associations to promote industry collaboration.
The aim is to jointly strengthen national conditions for precision medicine.
“For GMS, this agreement is a step towards creating improved and strengthened conditions for collaboration with industry. Through structured work, we will become a more obvious collaboration partner,” says Therese Fagerqvist, co-chair of GMS Innovation and Industry Collaboration.
The stakeholders will jointly contribute to the development of the field of precision medicine for the benefit of patients. This will be done by collaborating to develop, test and evaluate, among other things, diagnostics and analyses tools and therapies, as well as actively participating in other collaborative activities that will advance the field and contribute to the development and implementation of precision medicine. The aim is to strengthen Sweden’s enabling factors for precision medicine through collaboration with industry.
A framework for industry collaboration
The GMS partners have entered into an agreement with the industry associations Lif, Swedish Medtech, SwedenBIO and Swedish Labtech on a framework for industry collaboration. The framework aims to support and simplify collaboration between the GMS and industry actors in the life science sector.
The framework is a first step towards formalizing and strengthening the work on industry collaboration. The agreement aims to facilitate collaboration and clarify the conditions so that collaboration is mutually beneficial and developed in a trusting manner.
“A clear framework will make it easier. It will lead to closer collaboration and thereby speed up development – the knowledge of companies complements that of healthcare and academia.”
“The implementation of precision medicine is one of the most important steps in the development of healthcare. The life science companies and GMS share the ambition that Sweden should be at the forefront of its introduction so that it can benefit patients quickly. Achieving this goal requires cooperation, and we are therefore pleased that the agreement is in place. A clear framework will make it easier. It will lead to closer collaboration and thereby speed up development – the knowledge of companies complements that of healthcare and academia,” says Frida Lundmark, Policy Specialist, Lif.
The actors who have reached the agreement are: Region Skåne, Region Västra Götaland, Region Stockholm, Region Uppsala, Region Västerbotten, Region Örebro län and Region Östergötland, University of Gothenburg, Karolinska Institutet, Linköping University, Lund University, Umeå University, Uppsala University and Örebro University, together with the industry associations The research-based pharmaceutical industry (Lif), Swedish Medtech, SwedenBio and Swedish Labtech.